Our results indicate that ML-enhanced FET-PET analysis—compared to conventional FET-PET ROC analysis—may allow for better differentiation between pseudoprogression and true tumor progression in IDH-wildtype glioblastoma patients. The gene discussed is IDH2; the disease is glioblastoma.